ClinicalTrials.gg
Sign In
Drug

Fulzerasib clinical trials

Also written GFH925 and IBI351.

studies test it
10
open now
4
in phase 3
0
first study started
2021

How each study uses fulzerasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the fulzerasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

fulzerasib
1

Development codes

GFH925
4
IBI351
4

Studies by the year they started

10 studies that test it; most in 2023 (4)

Studies that test fulzerasib, by start year
YearStudies
20211
20222
20234
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
1
Colorectal Neoplasms
1

Who runs them

Industry 7 · Other 3

Innovent Biologics (Suzhou) Co. Ltd. (6) · Genfleet Therapeutics (Shanghai) Inc. (1) · Sun Yat-sen University (1) · Shanghai Chest Hospital (1) · Jianxing He (1)

Often tested with

Tested in the same studies.

Proteasomal Ubiquitin Receptor ADRM1 (1) · Tunlametinib (1) · Ivonescimab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Fulzerasib is the comparator. A study of two new drugs counts under both.

  • 1HRS-7058 · Shandong Suncadia Medicine Co., Ltd. · next primary completion May 2028
Reaching primary completion within a year · 2

Studies that test fulzerasib.

Studies

Open first, then newest update. How each study uses fulzerasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10

As the comparator · 1 — what is tested is compared with fulzerasib

Codes

What other systems call fulzerasib · ClinicalTrials.gg INT015248

  • UNII (FDA) 6D5B7F245WFULZERASIBOne source FDA
  • NCI Thesaurus C199055FulzerasibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.